1. Clinical Overview
Empagliflozin is a potent, selective, and competitive sodium-glucose co-transporter 2 (SGLT2) inhibitor used primarily in the management of type 2 diabetes mellitus (T2DM). It acts by reducing renal glucose reabsorption, leading to increased urinary glucose excretion (glucosuria) and a consequent reduction in plasma glucose levels. In the Indian context, it is a cornerstone of modern diabetes therapy, especially for patients with established cardiovascular or renal disease, as it has demonstrated significant cardiorenal protective benefits in landmark clinical trials (EMPA-REG OUTCOME).
| Onset | Duration | Bioavailability |
|---|---|---|
| The onset of action, as measured by increased urinary glucose excretion, occurs within 1-2 hours of oral administration. | The pharmacodynamic effect (glucosuria) persists for approximately 24 hours, supporting once-daily dosing. | Approximately 78% following oral administration. |
2. Mechanism of Action
Empagliflozin selectively and competitively inhibits the sodium-glucose co-transporter 2 (SGLT2) located in the proximal convoluted tubule of the nephron. SGLT2 is responsible for reabsorbing approximately 90% of the glucose filtered by the glomerulus. By inhibiting SGLT2, empagliflozin reduces the renal threshold for glucose (RTG), leading to increased excretion of glucose in the urine (glucosuria). This mechanism is independent of insulin secretion and beta-cell function.
3. Indications & Uses
- Type 2 Diabetes Mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
- To reduce the risk of cardiovascular death in adult patients with T2DM and established cardiovascular disease.
- To reduce the risk of sustained decline in eGFR, progression to end-stage kidney disease (ESKD), cardiovascular death, and hospitalization for heart failure in adults with T2DM and chronic kidney disease (CKD).
4. Dosage & Administration
Adult Dosage: The recommended starting dose is 10 mg once daily, taken in the morning, with or without food. The dose can be increased to 25 mg once daily for additional glycemic control or for cardiorenal protection.
Administration: Swallow the tablet whole with a glass of water. Can be taken with or without food, preferably in the morning. Maintain adequate fluid intake to prevent volume depletion. Monitor blood glucose and renal function periodically.
5. Side Effects
Common side effects may include:
- Genital mycotic infections (e.g., vulvovaginal candidiasis, balanitis).
- Increased urination (polyuria).
- Urinary tract infections (e.g., cystitis).
- Increased thirst.
- Headache.
- Dyslipidemia (increased LDL-cholesterol).
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Insulin or Insulin Secretagogues (Sulfonylureas, Meglitinides) | Increased risk of hypoglycemia. Dose reduction of insulin/secretagogue may be required. | Major |
| Loop Diuretics (Furosemide) | Additive diuretic effect; increased risk of volume depletion and hypotension. | Moderate |
| Lithium | Empagliflozin-induced diuresis may decrease lithium concentrations. Increased monitoring of lithium levels is recommended. | Moderate |
| Rifampicin | Induces UGT enzymes, potentially decreasing empagliflozin exposure. May reduce efficacy. | Moderate |
| Other SGLT2 Inhibitors | Additive pharmacodynamic effects; concomitant use is not recommended. | Major |
7. Patient Counselling
- DO take the tablet once daily, preferably in the morning.
- DO maintain adequate fluid intake to prevent dehydration.
- DO monitor your blood sugar levels as advised by your doctor.
- DO inform your doctor about all other medicines you are taking.
- DO practice good personal hygiene, especially genital hygiene, to prevent infections.
- DONT use this medicine if you are pregnant, planning pregnancy, or breastfeeding without consulting your doctor.
- DONT skip meals if you are also on insulin or medicines like sulfonylureas.
- DONT stop this medicine abruptly without consulting your doctor.
8. Toxicology & Storage
Overdose: Expected symptoms would be related to its pharmacodynamic effects: severe volume depletion (profound hypotension, tachycardia, syncope), hypoglycemia (if combined with other agents), and electrolyte imbalances (hyponatremia, hyperkalemia).
Storage: Store at room temperature (15°C to 30°C). Protect from moisture. Keep in the original blister pack or container. Keep out of reach and sight of children. Do not use after the expiry date printed on the pack.